IKK2-IN-3
Based on 1 Customer Validation
IKK2-IN-3 is an IKK2 inhibitor with an IC50 value of 0.075 μM. IKK2-IN-3 can be used for the research of cancer, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD).
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 916985-21-2
- Formula: C22H21N3O6S2
- Molecular Weight:487.55
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-120934
C25-140TRAF6-Ubc13 Inhibitor -
HY-112456
IKK2-IN-4IKK-2 Inhibitor -
HY-15473
MLN120BIKKβ Inhibitor -
HY-P2670
SN50MControl Peptide -
HY-112433
NIK SMI1NF-κB Inhibitor -
HY-15530
CID-2858522NF-κB Inhibitor -
HY-123936
SR12343IKK/NF-κB Inhibitor -
HY-107665
Ro 106-9920NF-κB Inhibitor -
HY-138284
Avenanthramide-C methyl esterNF-κB Inhibitor -
HY-116052
p53-MDM2-IN-2p53-MDM2 Inhibitor
Biological Activity
Description
IC50 & Target
|
IKK2 0.075 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
>30000 nM
Compound: 39
|
Antiproliferative activity against human HCT116 cells after 3 days by methylene blue stain technique
Antiproliferative activity against human HCT116 cells after 3 days by methylene blue stain technique
|
[PMID: 19097784] |
In Vitro
IKK2-IN-3 (Compound 8) inhibits IKK2 with an IC50 of 0.075 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 916985-21-2
-
Appearance Solid
-
Molecular Weight 487.55
-
Formula C22H21N3O6S2
-
Color White to off-white
-
SMILES
O=C(C1=C(OCC2=CC=C(S(=O)(C)=O)C=C2)C=C(N3C4=CC(OC)=C(OC)C=C4N=C3)S1)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (20.51 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0511 mL | 10.2554 mL | 20.5107 mL | 51.2768 mL |
| 5 mM | 0.4102 mL | 2.0511 mL | 4.1021 mL | 10.2554 mL | |
| 10 mM | 0.2051 mL | 1.0255 mL | 2.0511 mL | 5.1277 mL | |
| 15 mM | 0.1367 mL | 0.6837 mL | 1.3674 mL | 3.4185 mL | |
| 20 mM | 0.1026 mL | 0.5128 mL | 1.0255 mL | 2.5638 mL |
IKK2-IN-3 Related Classifications
HY-111135 Related Classifications
Powered by Bioz